
Ms Danielle Lang
Research Academic
School of Medicine and Public Health
- Email:danielle.lang@newcastle.edu.au
- Phone:(02) 4014 3002
Career Summary
Biography
Danielle leads the Newcastle Evaluation Group, which provides expert clinical and economic analysis to the Commonwealth Government to inform decisions regarding new medicines for the Pharmaceutical Benefits Scheme. Danielle first joined the Newcastle Evaluation Group as a health economist in 1998 and has gained extensive experience in economic modelling. Danielle has had a key role in developing economic evaluation teaching materials for the World Health Organization and has delivered these through short courses in low and middle income countries including South Africa, Hungary, Turkey, Thailand, Jordan and Uganda. Danielle has had reports of her scholarly work published in journals such as the Lancet and PLOS Medicine. She has also taught post-graduate health economics and economic evaluation at the Centre for Clinical Epidemiology and Biostatistics.
Qualifications
- Post Graduate Diploma in Health Economics and Eval, Monash University
- Bachelor of Mathematics/Bachelor of Economics, University of Newcastle
Keywords
- economic evaluation
- economic modelling
- health economics
- pharmacoeconomics
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Research Academic | University of Newcastle School of Medicine and Public Health Australia |
Research Academic | University of Newcastle School of Medicine and Public Health Australia |
Teaching
Code | Course | Role | Duration |
---|---|---|---|
PUBH6250 |
Health Economics The University of Newcastle |
Course Coordinator | 1/1/2004 - 19/9/2015 |
PUBH6260 |
Clinical Economics The University of Newcastle |
Course coordinator | 1/7/2003 - 19/9/2015 |
PUBH6290 |
Economic evaluation of health care University of Newcastle (previously PUBH6260 Clinical Economics) |
Course Coordinator | 1/7/2015 - 19/9/2015 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (10 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2020 |
Wall L, Hinwood M, Lang D, Smith A, Bunzli S, Clarke P, et al., 'Attitudes of patients and surgeons towards sham surgery trials: a protocol for a scoping review of attributes to inform a discrete choice experiment', BMJ OPEN, 10 (2020)
|
||||||||||
2015 |
Lang DL, Zhao FL, Robertson J, 'Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings', BMC Pregnancy and Childbirth, (2015) [C1] © 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization... [more] © 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization Model List of Essential Medicines for use in the prevention of postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available. Methods: A cost-consequences analysis was conducted from the international health system perspective, using data from a recent Cochrane systematic review and WHO's Mother-Baby Package Costing Spreadsheet in a hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were estimated based on 2012 US dollars. Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births, instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented. Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional 130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. These benefits need to be weighed against the large number of additional side effects such as shivering and fever, which have been described as tolerable and of short duration.
|
||||||||||
2007 |
Salkeld G, Henry DA, Hill SR, Lang DL, Freemantle N, D'Assuncao J, 'What drives health-care spending priorities? An international survey of health-care professionals', Plos Medicine, 4 256-259 (2007) [C1]
|
||||||||||
2003 |
Henry DA, Lang DL, 'Published pharmacoeconomic analyses: science or marketing?', Internal Medicine Journal, 33 404-404 (2003) [C3]
|
||||||||||
2003 |
Lopert R, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis - a technique for decision-making at the margin', Journal of Clinical Pharmacy and Therapeutics, 28 243-249 (2003) [C1]
|
||||||||||
2003 |
Robertson J, Lang DL, Hill SR, 'Use of pharmacoeconomics in prescribing research. Part 1: costs - moving beyond the acquisition price for drugs', Journal of Clinical Pharmacy and Therapeutics, 28 73-79 (2003) [C1]
|
||||||||||
2002 |
Lopert R, Lang DL, Hill SR, Henry DA, 'Differential pricing of drugs: a role for cost-effectiveness analysis?', The Lancet, 359 2105-2107 (2002) [C1]
|
||||||||||
1999 |
Whitworth J, Lang DL, Henry DA, 'Cost-effectiveness Analysis in the Treatment of Hypertension: A Medical View', Clinical and Experimental Hypertension, 21(5-6) 999-1008 (1999) [C1]
|
||||||||||
Show 7 more journal articles |
Conference (3 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2018 |
Wubishet B, Harris M, Lang D, Acharya S, Byles J, 'Rising diabetes prevalence among older Australian women', Melbourne, Australia (2018)
|
||||
2017 |
Wubishet B, Harris M, Abbas S, Lang D, acharya S, Byles J, 'Costs of major complications of Type 2 diabetes: A systematic review', Perth, Australia (2017)
|
||||
2017 |
Wubishet BL, Harris M, Abbas SS, Lang D, Acharya S, Byles J, 'COSTS OF MAJOR COMPLICATIONS OF TYPE 2 DIABETES: A SYSTEMATIC REVIEW', VALUE IN HEALTH (2017)
|
Report (1 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2001 |
Lowe J, Bonevski B, Carless P, Lopert R, Lang D, Deveridge S, et al., 'Universal Leucodepletion of Fresh Blood Products. A report comprising systematic review, stakeholder interviews and economic analysis', Commonwealth Department of Health and Aged Care (2001)
|
Grants and Funding
Summary
Number of grants | 9 |
---|---|
Total funding | $20,677,677 |
Click on a grant title below to expand the full details for that specific grant.
20201 grants / $178,382
Health Technology Assessment, Research Support and Other Services Panel$178,382
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan, Doctor Emily Walkom, Mr Jarrod Bell, Ms Lynn Goon, Doctor Madeleine Hinwood |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000297 |
Type Of Funding | C2110 - Aust Commonwealth - Own Purpose |
Category | 2110 |
UON | Y |
20161 grants / $6,798,376
Provision of external evaluation of Pharmaceutical Benefits Advisory Committee (PBAC) and health technology related submissions$6,798,376
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Ms Danielle Lang, Mr Jarrod Bell, Mr Rob Bell, Mr Marc Bevan, Ms Lynn Goon, Doctor Madeleine Hinwood, Doctor Emily Walkom, Miss Chiara Berardi |
Scheme | Consultancy/Tender |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2020 |
GNo | G1601071 |
Type Of Funding | C2110 - Aust Commonwealth - Own Purpose |
Category | 2110 |
UON | Y |
20141 grants / $53,923
Quotation for the provision of an evaluation of PBS Authority Required medicines using the Deed of Standing Offer SON 1503111 for the supply of PBS Medicines Review services$53,923
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Mr Rob Bell, Ms Danielle Lang, Mr Marc Bevan |
Scheme | Consultancy/Tender |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1400929 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20131 grants / $20,800
DoH Tender - Pharmaceutical Benefits Scheme (PBS) Medicines Review Panel$20,800
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Mr Marc Bevan, Mr Rob Bell, Ms Danielle Lang |
Scheme | Consultancy/Tender |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1300519 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20121 grants / $5,826,326
External Evaluation of PBAC Submissions RFT 086/1112 $5,826,326
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Ms Danielle Lang, Doctor Barrie Stokes, Mr Marc Bevan, Mr Rob Bell, Doctor Fei-Li Zhao |
Scheme | Consultancy/Tender |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2016 |
GNo | G1101212 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20091 grants / $4,534,474
External Evaluation of PBAC Submissions RFT 360/0708$4,534,474
Funding body: Department of Health
Funding body | Department of Health |
---|---|
Project Team | Doctor Jane Robertson, Ms Danielle Lang, Mr Rob Bell, Mr Marc Bevan |
Scheme | Consultancy/Tender |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2012 |
GNo | G0189557 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20051 grants / $3,221,378
External Evaluation of PBAC Submissions RFP 163/0304$3,221,378
Funding body: Commonwealth Department of Health & Aged Care
Funding body | Commonwealth Department of Health & Aged Care |
---|---|
Project Team | Ms Danielle Lang, Doctor Barrie Stokes, Doctor Jane Robertson |
Scheme | Consultancy/Tender |
Role | Lead |
Funding Start | 2005 |
Funding Finish | 2008 |
GNo | G0184477 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20041 grants / $1,066
2nd International Conference on Improving Use of Medicines (ICIUM2004), 30 March - 2 April 2004, Thailand$1,066
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Ms Danielle Lang |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2004 |
Funding Finish | 2004 |
GNo | G0183884 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20001 grants / $42,952
Local evaluation of the after hours primary medical care trial at Maitland Hospital.$42,952
Funding body: Hunter Urban Division of General Practice
Funding body | Hunter Urban Division of General Practice |
---|---|
Project Team | Conjoint Professor Dianne O'Connell, Ms Danielle Lang, Ms B Pekarsky |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2000 |
Funding Finish | 2000 |
GNo | G0180200 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Research Supervision
Number of supervisions
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2021 | PhD | Impact of Diabetes on Women's Health Outcomes: Survival, Healthy Life Expectancy, and Health Related Quality of Life | PhD (Health Economics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Projects
Patient and Surgeon preferences for sham surgery trials 2019 -
Publications
Wall L, Hinwood M, Lang D, Smith A, Bunzli S, Clarke P, et al., 'Attitudes of patients and surgeons towards sham surgery trials: a protocol for a scoping review of attributes to inform a discrete choice experiment', BMJ OPEN, 10 (2020)
Collaborators
Name | Organisation |
---|---|
Professor Francesco Paolucci | University of Newcastle |
Doctor Madeleine Hinwood | University of Newcastle |
Ms Danielle Leigh Lang | University of Newcastle |
Edit
Ms Danielle Lang
Position
Research Academic
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
danielle.lang@newcastle.edu.au | |
Phone | (02) 4014 3002 |
Fax | (02) 4960 2088 |
Office
Room | NM2.545 |
---|---|
Building | Calvary Mater Newcastle Level 5 - New Med 2 |
Location | Mater Hospital , |